Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$22.50 USD

22.50
10,175,243

-0.34 (-1.49%)

Updated Aug 6, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.

Tirthankar Chakraborty headshot

5 Top Efficient Stocks to Add to Your Portfolio

by Tirthankar Chakraborty

We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns

    Zacks Equity Research

    Edwards Lifesciences SAPIEN 3 Heart Valve Data Positive

    by Zacks Equity Research

    Edwards Lifesciences Corporation (EW) recently unveiled positive one-year data on its SAPIEN 3 transcatheter heart valve.

      Zacks Equity Research

      TransEnterix (TRXC) Reports Wider-than-Expected Loss in Q1

      by Zacks Equity Research

      TransEnterix, Inc. (TRXC) reported a loss of 13 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 12 cents.

        Zacks Equity Research

        Masimo (MASI) Beats on Q1 Earnings and Revenues, Guides Up

        by Zacks Equity Research

        Masimo Corp. (MASI) reported earnings of 57 cents per share in the first quarter of 2017, outperforming the Zacks Consensus Estimate of 54 cents and improving from the year-ago quarterly earnings of 53 cents.

          Zacks Equity Research

          Medtronic (MDT) Wins FDA Approval for CRT-P SureScan Suite

          by Zacks Equity Research

          Medtronic plc (MDT) recently won FDA approval for a portfolio of quadripolar cardiac resynchronization therapy-pacemakers that improve therapy delivery for patients with heart failure.

            Zacks Equity Research

            STERIS (STE) Grapples with Headwinds: Should You Dump?

            by Zacks Equity Research

            On May 10, we issued an updated research report on STERIS Plc (STE) which manufactures and markets infection prevention, decontamination, microbial reduction, and surgical and gastrointestinal support products and services.

              Tirthankar Chakraborty headshot

              New Strong Buy Stocks for May 12th

              by Tirthankar Chakraborty

              Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday

                Zacks Equity Research

                Hologic (HOLX) Tops Q2 Earnings & Sales, Raises 2017 View

                by Zacks Equity Research

                Hologic Inc. (HOLX) reported second-quarter fiscal 2017 adjusted earnings per share (EPS) of 50 cents, up 6.4% year over year.

                  Zacks Equity Research

                  Genomic Health (GHDX) Misses Q1 Earnings & Sales Estimates

                  by Zacks Equity Research

                  Genomic Health, Inc. (GHDX) reported first-quarter 2017 loss per share of 7 cents, reflecting an improvement from the year-ago quarter's loss figure of 19 cents.

                    Zacks Equity Research

                    Dull Q1 Earnings & Tough Industry Spell Trouble for BioScrip

                    by Zacks Equity Research

                    On May 10, we issued an updated research report on BioScrip, Inc. (BIOS ), a pure-play Infusion Service provider.

                      Zacks Equity Research

                      Becton (BDX) Announces $4.5B Follow-On Share Offerings

                      by Zacks Equity Research

                      Becton, Dickinson and Company (BDX), popularly known as BD, recently announced a follow-on offering of $4.5 billion for its shares.

                        Zacks Equity Research

                        STERIS (STE) Tops Q4 Earnings & Revenues, Issues '18 View

                        by Zacks Equity Research

                        STERIS Plc (STE) reported fourth-quarter fiscal 2017 adjusted earnings per share (EPS) of $1.11, up 23.3% from the year-ago quarter.

                          Zacks Equity Research

                          Penumbra (PEN) Q1 Loss Wider than Expected, View Intact

                          by Zacks Equity Research

                          Penumbra, Inc. (PEN), that went public in Sep 2015, reported first-quarter 2017 loss of 10 cents per share, comparing unfavorably with earnings of 7 cents year over year.

                            Zacks Equity Research

                            PetMed (PETS) Beats Earnings, Revenue Estimates in Q4

                            by Zacks Equity Research

                            PetMed Express, Inc. (PETS) announced earnings per share of 37 cents for the fourth quarter of fiscal 2017, up 37% from the year-ago quarter's 27 cents.

                              Zacks Equity Research

                              Henry Schein (HSIC) Tops Q1 Earnings, Reaffirms '17 View

                              by Zacks Equity Research

                              Henry Schein, Inc. (HSIC) reported adjusted earnings per share (EPS) of $1.76 in the first quarter of 2017, up 24.8% year over year.

                                Zacks Equity Research

                                Haemonetics (HAE) Tops Q4 Earnings, Sales, Issues 2018 View

                                by Zacks Equity Research

                                Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 39 cents in the fourth quarter of fiscal 2017, up 5.4% year over year.

                                  Zacks Equity Research

                                  Phibro (PAHC) Posts In Line Earnings in Q3, Revises View

                                  by Zacks Equity Research

                                  Phibro Animal Health Corporation (PAHC) reported adjusted earnings per share (EPS) of 37 cents in the third quarter of fiscal 2017, down 7.5% year over year.

                                    Zacks Equity Research

                                    Align Technology Invisalign Sales Strong, Currency Woes Stay

                                    by Zacks Equity Research

                                    On May 5, we issued an updated research report on Align Technology (ALGN), which manufactures a system of clear aligner therapy.

                                      Zacks Equity Research

                                      Qiagen Banks on Molecular Diagnostic amid Currency Woes

                                      by Zacks Equity Research

                                      On May 4, we issued an updated research report on leading molecular diagnostic company, Qiagen N.V. (QGEN).

                                        Zacks Equity Research

                                        CVS Down on Weak Earnings, Pharmacy Services Remains Strong

                                        by Zacks Equity Research

                                        On May 5, we issued an updated research report on Rhode Island-based pharmacy retail giant CVS Health Corp. (CVS).

                                          Zacks Equity Research

                                          VWR Corp (VWR) Beats on Q1 Earnings, Awaits Merger Closure

                                          by Zacks Equity Research

                                          VWR Corporation (VWR) reported first-quarter 2017 adjusted earnings per share (EPS) of 44 cents, reflecting a 10% rise from the year-ago quarter.

                                            Zacks Equity Research

                                            BioScrip (BIOS) Q1 Loss Narrower than Expected, Sales Miss

                                            by Zacks Equity Research

                                            BioScrip, Inc. (BIOS) reported net loss from continuing operations of $19.4 million or a loss of 18 cents per share in the first quarter of 2017 compared with net loss of $9.5 million or a loss of 17 cents a year ago.

                                              Zacks Equity Research

                                              Omnicell (OMCL) Q1 Loss Narrower than Expected, Revenues Lag

                                              by Zacks Equity Research

                                              Omnicell, Inc. (OMCL) reported a loss per share of 29 cents in first-quarter 2017, reflecting a deterioration from the year-ago loss of a penny.

                                                Zacks Equity Research

                                                Zacks.com featured highlights: Cott, Rogers, Baxter International, MKS Instruments and CSX

                                                by Zacks Equity Research

                                                Zacks.com featured highlights: Cott, Rogers, Baxter International, MKS Instruments and CSX

                                                  Zacks Equity Research

                                                  Cardiovascular Systems (CSII) Swings to Earnings in Q3

                                                  by Zacks Equity Research

                                                  Cardiovascular Systems, Inc. (CSII) reported adjusted earnings per share of 3 cents in third-quarter fiscal 2017, reflecting a massive improvement from the year-ago quarter's adjusted loss of 47 cents.